Great Debates and Updates in Hematologic Malignancies Archives
Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.
Jacqueline C. Barrientos, MD, MS, explains why combining therapies is beneficial for the treatment of patients with CLL.
Thomas G. Martin, MD, discusses MRD assessment in patients with multiple myeloma and how it may be able to influence therapy selection for these patients.
Daniel A. Pollyea, MD, MS, discusses novel therapies for ALL and how they are changing clinical practice.
Jacqueline C. Barrientos, MD, MS, explains the importance of sequencing monotherapy in chronic lymphocytic leukemia.
Richard R. Furman, MD, discusses ibrutinib compared with the standard chemoimmunotherapeutic regimen of intravenous fludarabine, cyclophosphamide, and rituximab, for patients with CLL.
Thomas G. Martin, MD, discusses promising immunotherapies in the pipeline for multiple myeloma and how they will affect the future treatment of this disease.
John P. Leonard, MD, presented an update on upfront and maintenance therapy in follicular lymphoma at the 2019 Great Debates and Updates in Hematologic Malignancies meeting.